Bisphosphonates Use and Risk of Subtrochanteric and Diaphyseal Femur Fractures in Korea: Results from the National Claim Registry

被引:0
作者
Young-Kyun Lee
Dong Won Byun
Sung-Mok Jung
Hye-Young Kwon
Ha-Young Kim
Se Hwa Kim
Tae-Young Kim
Sunmee Jang
Yong-Chan Ha
机构
[1] Seoul National University Bundang Hospital,Department of Orthopaedic Surgery
[2] Soonchunhyang University Hospital,Department of Endocrinology, Internal Medicine
[3] Hokkaido University,Graduate School of Medicine
[4] Mokwon University,Department of Biology & Public Health
[5] Wonkwang University Sanbon Hospital,Department of Internal Medicine
[6] Catholic Kwandong University College of Medicine,Department of Internal Medicine
[7] International St. Mary’s Hospital,Department of Orthopaedic Surgery, School of Medicine, Konkuk University Medical Center
[8] Konkuk University,College of Pharmacy and Gachon Institute of Pharmaceutical Sciences
[9] Gachon University,Department of Orthopaedic Surgery, School of Medicine
[10] Chung-Ang University,undefined
来源
Calcified Tissue International | 2019年 / 104卷
关键词
Bisphosphonates; Atypical femur fracture; Incidence rate; Korea;
D O I
暂无
中图分类号
学科分类号
摘要
Although Asian with bisphosphonate has been considered to have higher risk of subtrochanteric and diaphyseal femur (ST/DF) fractures, the occurrence of those fractures has been still unclear in Asia. The purpose of this study was to investigate the incidence rate of ST/DF fractures among bisphosphonate users from nationwide database in South Korea. Using national health insurance claim database, we only included the bisphosphonate users who took bisphosphonate for the first time in 2008 and evaluated the incidence rate of ST/DF fracture from 2008 to 2013. Non-user controls were matched to bisphosphonate users by propensity score matching with age and gender. Cox regression models were used to calculate hazard ratios of ST/DF fracture with and without adjustment for comorbidity. A total of 682 ST/DF fractures were observed among 348,311 bisphosphonate users. The incidence rate of ST/DF fracture among bisphosphonate users (37.75/100,000 person years, 95% CI 35.02–40.70) was higher compared with non-users (24.41/100,000 person years, 95% CI 22.31–26.71). The risk of ST/DF fracture was greater in bisphosphonate users compared with non-users (hazard ratio 1.541, 1.370–1.734; p < 0.001). The incidence rate of ST/DF fracture after bisphosphonate use could be determined in Korean patients, which can provide basal information for further studies on risk and benefit of continuing bisphosphonate.
引用
收藏
页码:313 / 319
页数:6
相关论文
共 258 条
  • [1] Ethgen O(2003)Health-related quality of life and cost of ambulatory care in osteoporosis: how may such outcome measures be valuable information to health decision makers and payers? Bone 32 718-724
  • [2] Tellier V(2006)An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 1726-1733
  • [3] Sedrine WB(2002)Diagnosis of osteoporosis and assessment of fracture risk Lancet 359 1929-1936
  • [4] De Maeseneer J(2008)Osteoporosis and fractures: missing the bridge? JAMA 299 1468-1470
  • [5] Gosset C(2007)Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men JAMA 298 629-637
  • [6] Reginster JY(2004)Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review Osteoporos Int 15 767-778
  • [7] Johnell O(2005)Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women Osteoporos Int 16 468-474
  • [8] Kanis JA(2001)Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis Osteoporos Int 12 S3-S10
  • [9] Kanis JA(1993)Bisphosphonates and osteoporosis Osteoporos Int 3 223-225
  • [10] Cheung AM(2006)Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing JAMA 296 2968-2969